Furthermore, FMT and SCFA administration reversed the CCH-induced imbalance in Tregs and Th17 cells by inhibiting differentiation of pathogenic Th17 cells and the IL-17 pathway, resulting in alleviation of impaired barrier function and chronic inflammation in colon tissues. This evidence concerns the gene IL17A and columnar cell hyperplasia of the breast.